Mini-BEAM regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} BCNU-Etoposide-AraC-Melphalan Regimen; Mini-BEAM Regimen ==Overview== {{PAGENAME}} refers to a dose-reduced variant of the BEA..." |
No edit summary |
||
| Line 9: | Line 9: | ||
==Regimen== | ==Regimen== | ||
{{chemo|B|Carmustine (BCNU)}} | {{chemo|B|Carmustine (BCNU)}} | ||
{{chemo|E|Etoposide}} | {{chemo|E|Etoposide}} | ||
{{chemo|A|Cytarabine (AraC)}} | {{chemo|A|Cytarabine (AraC)}} | ||
{{chemo|M|Melphalan}} | {{chemo|M|Melphalan}} | ||
==Indications== | ==Indications== | ||
*Relapsed or refractory [[Hodgkin's lymphoma]]<ref name="pmid7844600">{{cite journal| author=Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DM et al.| title=Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. | journal=J Clin Oncol | year= 1995 | volume= 13 | issue= 2 | pages= 396-402 | pmid=7844600 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7844600 }} </ref> | *Relapsed or refractory [[Hodgkin's lymphoma]]<ref name="pmid7844600">{{cite journal| author=Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DM et al.| title=Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. | journal=J Clin Oncol | year= 1995 | volume= 13 | issue= 2 | pages= 396-402 | pmid=7844600 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7844600 }} </ref> | ||
Latest revision as of 17:18, 27 March 2015
|
WikiDoc Resources for Mini-BEAM regimen |
|
Articles |
|---|
|
Most recent articles on Mini-BEAM regimen Most cited articles on Mini-BEAM regimen |
|
Media |
|
Powerpoint slides on Mini-BEAM regimen |
|
Evidence Based Medicine |
|
Cochrane Collaboration on Mini-BEAM regimen |
|
Clinical Trials |
|
Ongoing Trials on Mini-BEAM regimen at Clinical Trials.gov Trial results on Mini-BEAM regimen Clinical Trials on Mini-BEAM regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Mini-BEAM regimen NICE Guidance on Mini-BEAM regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Mini-BEAM regimen Discussion groups on Mini-BEAM regimen Patient Handouts on Mini-BEAM regimen Directions to Hospitals Treating Mini-BEAM regimen Risk calculators and risk factors for Mini-BEAM regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Mini-BEAM regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: BCNU-Etoposide-AraC-Melphalan Regimen; Mini-BEAM Regimen
Overview
Mini-BEAM regimen refers to a dose-reduced variant of the BEAM conditioning regimen used in the transplant setting, consisting of carmustine (bis-chloroethylnitrosourea, BCNU), etoposide, cytarabine (AraC), and melphalan and used for the treatment of relapsed or refractory Hodgkin's lymphoma.[1][2]
Regimen
BCarmustine (BCNU)
EEtoposide
ACytarabine (AraC)
MMelphalan
Indications
- Relapsed or refractory Hodgkin's lymphoma[2]
References
- ↑ "NCI Thesaurus".
- ↑ 2.0 2.1 Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DM; et al. (1995). "Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation". J Clin Oncol. 13 (2): 396–402. PMID 7844600.